Drug Discovery
ByHow Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences executes a precision oncology…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology, rare diseases, vaccines,…
EU Regulators Back CAMCEVI: A Key Step Toward Expanding Prostate Cancer Treatment Options
Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…
Can aTyr Pharma’s Upcoming FDA Meeting Accelerate the Path to Approval for Efzofitimod?
aTyr Pharma has reported its fourth-quarter and full-year 2025 financial results while outlining a pivotal regulatory milestone ahead:…
